PFA Pension Forsikringsaktieselskab Purchases Shares of 342,594 Amgen Inc. $AMGN

Key Points

• PFA Pension Forsikringsaktieselskab bought 342,594 Amgen shares in Q4, a stake valued at about $112.6 million that represented roughly 0.06% of the company at filing.
• Amgen beat Q1 EPS expectations ($5.15) and set FY‑2026 guidance of $21.70–$23.10, declared a $2.52 quarterly dividend (annualized $10.08, ~3.1% yield), but shares traded down ~4.7% amid mixed analyst reactions and an FDA regulatory risk tied to Tavneos.

PFA Pension Forsikringsaktieselskab purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 342,594 shares of the medical research company's stock, valued at approximately $112,607,000. PFA Pension Forsikringsaktieselskab owned about 0.06% of Amgen at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in AMGN. Capital World Investors increased its position in shares of Amgen by 11.5% during the third quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company's stock valued at $17,949,296,000 after acquiring an additional 961,975 shares during the last quarter. National Bank of Canada FI increased its position in shares of Amgen by 237.7% during the third quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company's stock valued at $346,076,000 after acquiring an additional 863,216 shares during the last quarter. Van ECK Associates Corp increased its position in shares of Amgen by 71.8% during the third quarter. Van ECK Associates Corp now owns 1,358,092 shares of the medical research company's stock valued at $383,254,000 after acquiring an additional 567,400 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Amgen by 91.6% during the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company's stock valued at $221,607,000 after acquiring an additional 375,463 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Q1 results beat expectations — AMGN reported $5.15 EPS vs. $4.73 consensus and product sales rose ~4%, with 16 drugs delivering double‑digit growth, supporting the company’s growth story. Amgen's Q1 Earnings Top Estimates
• Positive Sentiment: Bullish analyst action — Goldman Sachs reiterated a Buy and lifted its price target to $425, signaling long‑term upside from execution and pipeline momentum. Goldman Sachs Raises PT to $425
• Positive Sentiment: Other supportive analyst notes — Some firms (e.g., William Blair) reiterated Buy ratings after the quarter, highlighting confidence in the MariTide/weight‑loss program and execution. Analyst Reiterates Buy
• Neutral Sentiment: Guidance set but roughly in line — Amgen updated FY‑2026 EPS guidance to $21.70–$23.10 (consensus ~22.29), which many read as broadly in‑line rather than materially bullish. Amgen FY2026 Guidance (press release/slide)
• Neutral Sentiment: Small, mixed analyst target moves — Truist nudged its target to $327 with a Hold rating (minimal change), leaving some investors watching for clearer directional signals. Truist Raises PT to $327
• Negative Sentiment: FDA action risk — The FDA proposed withdrawing Tavneos approval after alleging clinical‑trial data issues, raising regulatory, compliance and reputational concerns that can pressure the stock. FDA Tavneos Proposal Coverage
• Negative Sentiment: Investor apprehension over strategy/timing — Some market commentary framed the quarter as “generally in‑line” and expressed concern about Amgen’s aggressive push into obesity (MariTide) and the near‑term profit impact, contributing to selling pressure. Investor Reaction to MariTide Expansion

Amgen Trading Down 4.7%

Shares of AMGN stock opened at $329.82 on Friday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market capitalization of $178.00 billion, a P/E ratio of 23.18, a price-to-earnings-growth ratio of 3.42 and a beta of 0.47. The company has a 50 day moving average price of $358.07 and a 200 day moving average price of $340.45. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts' expectations of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 139.90%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.16 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen's payout ratio is currently 70.84%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AMGN shares. Sanford C. Bernstein cut shares of Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the company a "sell" rating in a research report on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a research report on Thursday, February 5th. Mizuho lifted their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an "outperform" rating in a report on Tuesday, February 10th. Finally, Royal Bank Of Canada lifted their price objective on shares of Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, Amgen currently has a consensus rating of "Hold" and an average price target of $357.54.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.